CIC CBIC Certified Infection Control Exam Free Practice Exam Questions (2026 Updated)

Assessing the effectiveness of an infection control action plan is a critical responsibility of an infection preventionist (IP) to ensure that interventions reduce healthcare-associated infections (HAIs) and improve patient safety. The Certification Board of Infection Control and Epidemiology (CBIC) highlights this process within the "Surveillance and Epidemiologic Investigation" and "Performance Improvement" domains, emphasizing the need for ongoing evaluation and data-driven decision-making. The Centers for Disease Control and Prevention (CDC) and other guidelines stress that the ultimate goal of an action plan is to achieve measurable outcomes, such as reduced infection rates, which requires systematic monitoring and validation.

Option D, "Monitor and validate the related outcome and process measures," is the most important consideration. Outcome measures (e.g., infection rates, morbidity, or mortality) indicate whether the action plan has successfully reduced the targeted infection risk, while process measures (e.g., compliance with hand hygiene or proper catheter insertion techniques) assess whether the implemented actions are being performed correctly. Monitoring involves continuous data collection and analysis, while validation ensures the data’s accuracy and relevance to the plan’s objectives. The CBIC Practice Analysis (2022) underscores that effective infection control relies on evaluating both outcomes (e.g., decreased central line-associated bloodstream infections) and processes (e.g., adherence to aseptic protocols), making this a dynamic and essential step. The CDC’s "Compendium of Strategies to Prevent HAIs" (2016) further supports this by recommending regular surveillance and feedback as key to assessing intervention success.

Option A, "Re-evaluate the action plan every three years," suggests a periodic review, which is a good practice for long-term planning but is insufficient as the most important consideration. Infection control requires more frequent assessment (e.g., quarterly or annually) to respond to emerging risks or outbreaks, making this less critical than ongoing monitoring. Option B, "Update the plan before the risk assessment is completed," is illogical and counterproductive. Updating a plan without a completed risk assessment lacks evidence-based grounding, undermining the plan’s effectiveness and contradicting the CBIC’s emphasis on data-driven interventions. Option C, "Develop a timeline and assign responsibilities for the stated action," is an important initial step in implementing an action plan, ensuring structure and accountability. However, it is a preparatory activity rather than the most critical factor in assessing effectiveness, which hinges on post-implementation evaluation.

The CBIC Practice Analysis (2022) and CDC guidelines prioritize outcome and process monitoring as the cornerstone of infection control effectiveness, enabling IPs to adjust strategies based on real-time evidence. Thus, Option D represents the most important consideration for assessing an infection control action plan’s success.

The correct answer is C, "Toxic Anterior Segment Syndrome," as this is the inflammatory reaction that may occur in the eye after cataract surgery due to a breach in disinfection and sterilization of intraocular surgical instruments. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, Toxic Anterior Segment Syndrome (TASS) is a sterile, acute inflammatory reaction that can result from contaminants introduced during intraocular surgery, such as endotoxins, residues from improper cleaning, or chemical agents left on surgical instruments due to inadequate disinfection or sterilization processes (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). TASS typically presents within 12-48 hours post-surgery with symptoms like pain, redness, and anterior chamber inflammation, and it is distinct from infectious causes because it is not microbial in origin. A breach in reprocessing protocols, such as failure to remove detergents or improper sterilization, is a known risk factor, making it highly relevant to infection prevention efforts in surgical settings.

Option A (endophthalmitis) is an infectious inflammation of the internal eye structures, often caused by bacterial or fungal contamination, which can also result from poor sterilization but is distinguished from TASS by its infectious nature and longer onset (days to weeks). Option B (bacterial conjunctivitis) affects the conjunctiva and is typically a surface infection unrelated to intraocular surgery or sterilization breaches of surgical instruments. Option D (toxic posterior segment syndrome) is not a recognized clinical entity in the context of cataract surgery; inflammation in the posterior segment is more commonly associated with infectious endophthalmitis or other conditions, not specifically linked to reprocessing failures.

The focus on TASS aligns with CBIC’s emphasis on ensuring safe reprocessing to prevent adverse outcomes in surgical patients, highlighting the need for rigorous infection control measures (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.5 - Evaluate the environment for infection risks). This is supported by CDC and American Academy of Ophthalmology guidelines, which identify TASS as a preventable complication linked to reprocessing errors (CDC Guidelines for Disinfection and Sterilization, 2019; AAO TASS Task Force Report, 2017).

Chlorhexidine-impregnated dressings reduce central line-associated bloodstream infections (CLABSI) by preventing bacterial colonization​.

Routine catheter replacement (A) increases insertion risks without reducing infections.

Daily blood cultures (C) are unnecessary and lead to false positives.

Povidone-iodine (D) is less effective than chlorhexidine for skin antisepsis.

CBIC Infection Control References:

APIC Text, "CLABSI Prevention Measures," Chapter 10​.

The correct answer is B, "Pre-cleaning, leak testing, and manual cleaning," as these processes are essential for endoscope reprocessing. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, proper reprocessing of endoscopes is critical to prevent healthcare-associated infections (HAIs), given their complex design and susceptibility to microbial contamination. The initial steps of pre-cleaning (removing gross debris at the point of use), leak testing (ensuring the endoscope’s integrity to prevent fluid ingress), and manual cleaning (using enzymatic detergents to remove organic material) are foundational to the reprocessing cycle. These steps prepare the endoscope for high-level disinfection or sterilization by reducing bioburden and preventing damage, as outlined in standards such as AAMI ST91 (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). Failure at this stage can compromise subsequent disinfection, making it a non-negotiable component of the process.

Option A (intermediate level disinfection and contact time) is an important step but insufficient alone, as intermediate-level disinfection does not achieve the high-level disinfection required for semi-critical devices like endoscopes, which must eliminate all microorganisms except high levels of bacterial spores. Option C (inspection using a borescope and horizontal storage) includes valuable quality control (inspection) and storage practices, but these occur later in the process and are not essential initial steps; vertical storage is often preferred to prevent damage. Option D (leak testing, manual cleaning, and low level disinfection) includes two essential steps (leak testing and manual cleaning) but is inadequate because low-level disinfection does not meet the standard for endoscopes, which require high-level disinfection or sterilization.

The emphasis on pre-cleaning, leak testing, and manual cleaning aligns with CBIC’s focus on adhering to evidence-based reprocessing protocols to ensure patient safety and prevent HAIs (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.4 - Implement environmental cleaning and disinfection protocols). These steps are mandated by guidelines to mitigate risks associated with endoscope use in healthcare settings.

The CBIC Certified Infection Control Exam Study Guide (6th edition) clearly states that the correct and recommended method for obtaining urine cultures in patients with an indwelling urinary catheter is to collect the specimen using aseptic technique from the catheter’s designated sampling (collection) port. This method minimizes the risk of contamination and provides the most accurate reflection of organisms present in the urinary tract.

Urine collected from the sampling port is obtained after disinfecting the port and aspirating urine with a sterile syringe. This approach maintains the integrity of the closed drainage system and reduces the introduction of microorganisms. Accurate culture collection is essential for correct diagnosis of catheter-associated urinary tract infection (CAUTI) and for distinguishing true infection from colonization or contamination.

Option B is incorrect because culturing the catheter tip is not recommended for diagnosing CAUTI; it does not reliably represent urinary tract pathogens and may reflect biofilm colonization. Option C is inappropriate because disconnecting the catheter from the drainage tubing breaks the closed system and increases infection risk. Option D is incorrect because urine from the drainage bag is often contaminated and does not accurately represent bladder urine.

For CIC® exam preparation, it is critical to recognize that aseptic aspiration from the catheter sampling port is the standard of care for urine culture collection in catheterized patients and is a core infection prevention principle related to CAUTI surveillance and diagnosis.

==========

When evaluating a new disinfectant, the infection preventionist's primary concern must be the safety and effectiveness of the product. This includes ensuring the product is EPA-registered, effective against targeted pathogens, safe for both the environment and users, and compliant with regulatory guidelines.

From the APIC/JCR Workbook, key considerations include:

“Organizations should evaluate each product to ensure that it can be used safely and include a review of dilutions, storage, shelf life, PPE needed, and disposal and ventilation requirements to ensure that OSHA, EPA, or local requirements are met”.

The CBIC Study Guide reinforces that:

"Safety and efficacy are critical factors in evaluating new products, with particular emphasis on infection prevention and user safety".

The other options, while relevant, are not the most critical factors in determining product adoption from an infection control standpoint.

The CBIC Certified Infection Control Exam Study Guide (6th edition) identifies clindamycin as one of the antimicrobials most strongly associated with an increased risk of Clostridioides difficile infection (CDI). Clindamycin has a profound impact on the normal intestinal microbiota, significantly disrupting protective gut flora that ordinarily suppress C. difficile overgrowth. This disruption creates an environment conducive to colonization and toxin production by C. difficile, leading to clinical infection.

Historically, clindamycin was one of the first antibiotics clearly linked to large outbreaks of CDI, and it remains a high-risk agent today. The Study Guide notes that antibiotics with broad anaerobic coverage—including clindamycin, fluoroquinolones, third-generation cephalosporins, and carbapenems—are particularly associated with CDI because they extensively alter gastrointestinal microbial balance.

The other options listed carry comparatively lower risk. Amoxicillin has a modest association but is not among the highest-risk agents. Aztreonam has limited anaerobic activity and is less disruptive to gut flora. Tobramycin, an aminoglycoside, has minimal impact on intestinal microbiota when administered parenterally and is not commonly associated with CDI.

Recognizing high-risk antimicrobials is essential for antimicrobial stewardship, CDI prevention strategies, and CIC® exam success. Clindamycin is classically tested and should be readily identified as a major CDI risk factor.

The CBIC Certified Infection Control Exam Study Guide (6th edition) emphasizes that patients who have undergone splenectomy are at significantly increased risk for overwhelming postsplenectomy infection (OPSI), a rapidly progressive and potentially fatal condition. The spleen plays a critical role in clearing encapsulated organisms, and its absence markedly increases susceptibility to infections caused by these pathogens.

Among encapsulated bacteria, Streptococcus pneumoniae is the most common and most deadly cause of OPSI, making pneumococcal vaccination the single most important immunization for asplenic patients. Pneumococcal disease in individuals without a spleen can progress rapidly to sepsis, meningitis, or death, even in young and otherwise healthy adults. Therefore, ensuring pneumococcal vaccination—using the appropriate conjugate and polysaccharide vaccines according to age and immunization history—is a top priority.

While Haemophilus influenzae type B (Option A) and meningococcal vaccines are also recommended for asplenic patients, pneumococcal vaccination provides the greatest immediate protection against the most common cause of severe infection. Hepatitis B (Option C) and varicella (Option D) are important routine immunizations but are not specifically related to the increased infection risk associated with asplenia.

For the CIC® exam, it is critical to recognize that loss of splenic function necessitates prioritization of vaccines targeting encapsulated organisms, with pneumococcal vaccination being the most important.

The interaction between pathogens and the human body can take various forms, each with distinct immunological and clinical implications. The Certification Board of Infection Control and Epidemiology (CBIC) emphasizes understanding these states within the "Identification of Infectious Disease Processes" domain to guide infection prevention strategies. The question describes a scenario where pathogens are present, can be cultured (indicating viable organisms), but do not trigger a response from the body’s defense mechanisms, such as inflammation or immune activation. This requires identifying the appropriate microbiological state.

Option A, "Colonization," is the correct answer. Colonization occurs when microorganisms are present on or in the body (e.g., skin, mucous membranes, or gut) without causing harm or eliciting an immune response. These pathogens can be cultured, as they are alive and replicating, but they exist in a commensal or symbiotic relationship with the host, not provoking symptoms or defense mechanisms. Examples include normal flora like Staphylococcus epidermidis on the skin or Streptococcus salivarius in the oral cavity. The Centers for Disease Control and Prevention (CDC) defines colonization as the presence of microbes without tissue invasion or damage, distinguishing it from infection (CDC, "Principles of Epidemiology in Public Health Practice," 3rd Edition, 2012).

Option B, "Infection," is incorrect because it involves the invasion and multiplication of pathogens in body tissues, leading to an immune response, such as inflammation, fever, or antibody production. This contrasts with the question’s description of no defense mechanism response. Option C, "Latency," refers to a state where a pathogen (e.g., herpes simplex virus or Mycobacterium tuberculosis) remains dormant in the body after initial infection, capable of reactivation but not eliciting an active immune response during dormancy. However, latency implies a prior infection with a latent phase, whereas the question suggests a current, non-responsive state without prior infection context. Option D, "Contamination," describes the unintended presence of pathogens on inanimate objects or surfaces (e.g., medical equipment), not within the body, and does not align with the scenario of living, culturable pathogens in a host.

The CBIC Practice Analysis (2022) and CDC guidelines highlight colonization as a key concept in infection control, particularly in settings like hospitals where colonized patients can serve as reservoirs for potential infections. The absence of an immune response, as specified, aligns with the definition of colonization, making Option A the most accurate answer.

The correct answer is D, "A device used one time on a patient during a procedure and then discarded," as this accurately describes a single-use medical device. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, a single-use device (SUD), also known as a disposable device, is labeled by the manufacturer for one-time use on a patient and is intended to be discarded afterward to prevent cross-contamination and ensure patient safety. This definition is consistent with regulations from the Food and Drug Administration (FDA), which designate SUDs as devices that should not be reprocessed or reused due to risks of infection, material degradation, or failure to restore sterility (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). Examples include certain syringes, catheters, and gloves, which are designed for single use to eliminate the risk of healthcare-associated infections (HAIs).

Option A (a device which can be used on a single patient) is too vague and could apply to both single-use and reusable devices, as reusable devices are also often used on a single patient per procedure before reprocessing. Option B (a device that is sterilized and can be used again on the same patient) describes a reusable device, not a single-use device, as sterilization and reuse are not permitted for SUDs. Option C (a device used on a patient and reprocessed prior to being used again) refers to a reusable device that undergoes reprocessing (e.g., sterilization), which is explicitly prohibited for SUDs under manufacturer and regulatory guidelines.

The focus on discarding after one use aligns with CBIC’s emphasis on preventing infection through adherence to device labeling and safe reprocessing practices, ensuring that healthcare facilities avoid the risks associated with improper reuse of SUDs (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.5 - Evaluate the environment for infection risks). This practice is critical to maintaining a sterile and safe healthcare environment.

To determine which surgeon has the highest surgical site infection (SSI) rate, use the following formula:

Since Dr. White has the highest SSI rate at 9.1%, the correct answer is D. White.

CBIC Infection Control Reference

SSI rates are calculated using infection count per total procedures and reported as percentage values​.

The best response for an infection preventionist (IP) when receiving a news media call during a COVID outbreak with hospital-associated transmission cases is to refer the reporters to the hospital's media spokesperson. This approach aligns with the principles outlined in the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, which emphasize the importance of maintaining professionalism, protecting patient privacy, and ensuring accurate communication. The IP's primary role is to focus on infection prevention and control activities rather than serving as a public relations representative. Engaging directly with the media can risk divulging sensitive patient information or operational details that may not be fully contextualized, potentially violating the Health Insurance Portability and Accountability Act (HIPAA) or other privacy regulations.

Option A (answer the questions truthfully) is not ideal because, while truthfulness is important, the IP may not have the authority or full context to provide a comprehensive and accurate public statement, and doing so could inadvertently compromise patient confidentiality or misrepresent hospital policies. Option B (give vague answers to ensure patient privacy) might protect privacy but could lead to miscommunication or lack of trust if the responses appear evasive without a clear referral process. Option D (inform the reporter that the conversation must be recorded to ensure accuracy) is a procedural step but does not address the core issue of who should handle media inquiries.

Referring to the hospital's media spokesperson (Option C) ensures that a trained individual handles the communication, adhering to CBIC's emphasis on collaboration with organizational leadership and adherence to institutional communication protocols (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.1 - Collaborate with organizational leaders). This also aligns with best practices for managing public health crises, where centralized and coordinated messaging is critical to avoid misinformation.

The Certification Study Guide (6th edition) identifies environmental dispersal of microorganisms as the primary reason healthcare construction and renovation activities increase the risk of healthcare-associated infections (HAIs). Construction activities such as demolition, drilling, and ceiling penetration disturb dust and building materials that may harbor fungal spores and other microorganisms, particularly Aspergillus species. Once aerosolized, these organisms can spread through airflow to patient care areas if containment and ventilation controls are inadequate.

The study guide emphasizes that immunocompromised patients—such as those in oncology units, transplant units, and intensive care settings—are especially vulnerable to infections caused by airborne fungi released during construction. Numerous outbreaks of invasive aspergillosis have been linked directly to renovation and construction projects that lacked appropriate infection control risk assessment (ICRA) measures.

The incorrect options describe secondary or contributory issues but are not the primary mechanism of infection risk. While increased personnel traffic, hand hygiene training, and waste handling are important considerations, they do not represent the central hazard posed by construction. The fundamental risk is airborne dissemination of microorganisms from disrupted environmental reservoirs.

CIC exam questions frequently test knowledge of construction-related infection risks and the importance of engineering controls such as negative pressure containment, HEPA filtration, and dust barriers. Recognizing environmental dispersal as the primary risk underscores why rigorous planning and infection control oversight are essential during renovation projects.

The most critical factor in choosing disinfectants in long-term care is compatibility with medical devices to prevent damage and ensure safety. Improper selection can compromise disinfection efficacy and equipment longevity.

The APIC/JCR Workbook highlights:

“Organizations should evaluate compatibility of disinfectant products with the materials used in patient care equipment. Incompatibility can lead to equipment degradation or malfunction”.

This ensures compliance with manufacturer instructions and preserves warranty and functionality.

10% lipid emulsions are the most likely to promote microbial growth because they provide an ideal environment for bacterial and fungal proliferation, especially Staphylococcus aureus, Pseudomonas aeruginosa, and Candida species. Lipids support rapid bacterial multiplication due to their high nutrient content.

Why the Other Options Are Incorrect?

A. 50% hypertonic glucose – High glucose concentrations inhibit bacterial growth due to osmotic pressure effects.

B. 5% dextrose – While it can support some bacterial growth, it is less favorable than lipid emulsions.

C. Synthetic amino acids – These solutions do not support microbial growth as well as lipid emulsions.

CBIC Infection Control Reference

APIC guidelines confirm that lipid-based solutions support rapid microbial growth and should be handled with strict aseptic technique​.

The correct answer is D, "Manufacturer representatives," as they are responsible for providing information regarding clinical trials when evaluating environmental cleaning and disinfectant products as part of the product evaluation committee. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, manufacturers are the primary source of data on the efficacy, safety, and performance of their products, including clinical trial results that demonstrate the disinfectant’s ability to reduce microbial load or prevent healthcare-associated infections (HAIs) (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.4 - Implement environmental cleaning and disinfection protocols). This information is critical for the committee to assess whether the product meets regulatory standards (e.g., EPA registration) and aligns with infection prevention goals, and it is typically supported by documentation such as peer-reviewed studies or trial data provided by the manufacturer.

Option A (Infection Preventionist) plays a key role in evaluating the product’s fit within infection control practices and may contribute expertise or conduct internal assessments, but they are not responsible for providing clinical trial data, which originates from the manufacturer. Option B (Clinical representatives) can offer insights into clinical usage and outcomes but rely on manufacturer data for trial evidence rather than generating it. Option C (Environmental Services) focuses on the practical application and cleaning processes but lacks the authority or resources to conduct or provide clinical trial information.

The reliance on manufacturer representatives aligns with CBIC’s emphasis on evidence-based decision-making in product selection, ensuring that the product evaluation committee bases its choices on robust, manufacturer-supplied clinical data (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 - Use data to guide infection prevention and control strategies). This approach supports the safe and effective implementation of environmental cleaning products in healthcare settings.

The Certification Study Guide (6th edition) explains that graphs are most effective when they clearly communicate who, what, when, and how regarding the data being presented. Essential elements include a descriptive title, identification of the facility and time frame, and properly labeled X and Y axes with annotations as needed. These components ensure that the viewer can accurately interpret the data without additional explanation.

Published trends for data comparison, while potentially useful in separate analyses or reports, are not required elements of an individual graph and do not inherently improve the clarity of data display. Including external published trends can actually confuse interpretation if definitions, populations, or surveillance methodologies differ from the local data being presented. The study guide cautions against mixing datasets with different assumptions or collection methods in a single visual display unless clearly contextualized.

Titles clarify the subject of the graph, facility and time frame provide essential context, and axis labels ensure the viewer understands what is being measured. These are foundational principles of data visualization emphasized in infection prevention reporting and communication.

CIC exam questions frequently test the ability to distinguish between essential graph components and supplementary analytical tools. Recognizing that published comparison trends are not required—and may be misleading—reinforces good data communication practices and supports accurate interpretation by leadership and frontline staff.

The correct answer is B, "The sterility is not maintained during storage," as this represents a key limitation of using liquid chemical sterilants to sterilize medical items. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines and standards from the Association for the Advancement of Medical Instrumentation (AAMI), liquid chemical sterilants, such as glutaraldehyde or peracetic acid, are effective for sterilizing heat-sensitive medical devices by eliminating all forms of microbial life, including spores, when used according to manufacturer instructions (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). However, a significant limitation is that sterility is not guaranteed after the items are removed from the sterilant and stored, as the sterile barrier can be compromised by environmental contamination, improper packaging, or handling (AAMI ST58:2013, Chemical Sterilization and High-Level Disinfection in Health Care Facilities).

Option A (it does not kill the spores) is incorrect because liquid chemical sterilants are designed to achieve sterilization, including the destruction of bacterial spores, provided the contact time, concentration, and conditions specified by the manufacturer are met. Option C (it requires a contact time of at least 12 hours) is not a universal limitation; while some liquid sterilants require extended contact times (e.g., 10-12 hours for certain formulations), this is a procedural requirement rather than an inherent limitation, and shorter times may be sufficient with other agents or automated systems. Option D (it can only be used for heat tolerant devices) is incorrect because liquid chemical sterilants are specifically intended for heat-sensitive devices that cannot withstand steam or dry heat sterilization.

The limitation of sterility not being maintained during storage underscores the need for immediate use of sterilized items or the use of proper sterile packaging and storage protocols to prevent recontamination. This aligns with CBIC’s focus on ensuring the safety and efficacy of reprocessed medical equipment in infection prevention (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). Healthcare facilities must implement strict post-sterilization handling and storage practices to mitigate this limitation.

Coliform bacteria are indicators of fecal contamination in water, making them a critical measure of water safety. Hepatitis A is a virus primarily transmitted via the fecal-oral route, often through contaminated food or water.

Step-by-Step Justification:

Fecal Contamination and Hepatitis A:

Hepatitis A virus (HAV) spreads through ingestion of water contaminated with fecal matter. High coliform counts indicate fecal contamination and increase the risk of HAV outbreaks​.

Use of Coliforms as Indicators:

Public health agencies use total coliforms and Escherichia coli (E. coli) as primary indicators of water safety because they signal fecal pollution​.

Waterborne Transmission of Hepatitis A:

Hepatitis A outbreaks have been traced to contaminated drinking water, ice, and improperly treated wastewater. Coliform detection signals a need for immediate action​.

Why Other Options Are Incorrect:

B. Pseudomonads:

Pseudomonads (e.g., Pseudomonas aeruginosa) are environmental bacteria but are not indicators of fecal contamination.

C. Legionella:

Legionella species cause Legionnaires' disease through inhalation of contaminated aerosols, not through fecal-oral transmission.

D. Acinetobacter:

Acinetobacter species are opportunistic pathogens in healthcare settings but are not indicators of waterborne fecal contamination.

CBIC Infection Control References:

APIC Text, "Water Systems and Infection Control Measures"​.

APIC Text, "Hepatitis A Transmission and Waterborne Outbreaks"​.